174 related articles for article (PubMed ID: 35454873)
1. A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8
Vu PL; Vadakekolathu J; Idri S; Nicholls H; Cavaignac M; Reeder S; Khan MA; Christensen D; Pockley AG; McArdle SE
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454873
[TBL] [Abstract][Full Text] [Related]
2. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
3. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Johnson LE; McNeel DG
Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
6. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
Wieckowski E; Chatta GS; Mailliard RM; Gooding W; Palucka K; Banchereau J; Kalinski P
Prostate; 2011 Feb; 71(2):125-33. PubMed ID: 20717900
[TBL] [Abstract][Full Text] [Related]
7. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
Antonarakis ES; Small EJ; Petrylak DP; Quinn DI; Kibel AS; Chang NN; Dearstyne E; Harmon M; Campogan D; Haynes H; Vu T; Sheikh NA; Drake CG
Clin Cancer Res; 2018 Oct; 24(19):4662-4671. PubMed ID: 29858218
[No Abstract] [Full Text] [Related]
8. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
[TBL] [Abstract][Full Text] [Related]
9. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
10. TGM4: an immunogenic prostate-restricted antigen.
Lopez-Bujanda ZA; Obradovic A; Nirschl TR; Crowley L; Macedo R; Papachristodoulou A; O'Donnell T; Laserson U; Zarif JC; Reshef R; Yuan T; Soni MK; Antonarakis ES; Haffner MC; Larman HB; Shen MM; Muranski P; Drake CG
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193566
[TBL] [Abstract][Full Text] [Related]
11. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
12. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
13. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
14. An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.
Spies E; Reichardt W; Alvarez G; Groettrup M; Ohlschläger P
Mol Ther; 2012 Mar; 20(3):555-64. PubMed ID: 22086231
[TBL] [Abstract][Full Text] [Related]
15. Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and
Johnson LE; Brockstedt D; Leong M; Lauer P; Theisen E; Sauer JD; McNeel DG
Oncoimmunology; 2018; 7(8):e1456603. PubMed ID: 30221049
[No Abstract] [Full Text] [Related]
16. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
Olson BM; McNeel DG
Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
18. A Novel HAGE/WT1-ImmunoBody
Almshayakhchi R; Nagarajan D; Vadakekolathu J; Guinn BA; Reeder S; Brentville V; Metheringham R; Pockley AG; Durrant L; McArdle S
Front Oncol; 2021; 11():636977. PubMed ID: 34262856
[TBL] [Abstract][Full Text] [Related]
19. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
[TBL] [Abstract][Full Text] [Related]
20. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
